Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02535416




Registration number
NCT02535416
Ethics application status
Date submitted
24/08/2015
Date registered
28/08/2015

Titles & IDs
Public title
A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers
Scientific title
A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 at Varying Infusion Rates in Normal Adult Volunteers
Secondary ID [1] 0 0
Heparc-1002
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: ARC-520 Cohort 1 - Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.6 mL/min + cetirizine

Experimental: ARC-520 Cohort 2A - Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + cetirizine

Experimental: ARC-520 Cohort 2 - Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.75 mL/min + diphenhydramine

Experimental: ARC-520 Cohort 3 - Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 0.9 mL/min + diphenhydramine

Experimental: ARC-520 Cohort 4 - Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.2 mL/min + diphenhydramine

Experimental: ARC-520 Cohort 5 - Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 1.5 mL/min + diphenhydramine

Experimental: ARC-520 Cohort 6 - Single dose, intravenous administration of ARC-520 at 4.0 mg/kg 5 minute slow bolus push + diphenhydramine

Experimental: ARC-520 Cohort 7 - Single dose, intravenous administration of ARC-520 at 5.0 mg/kg 0.9 mL/min + diphenhydramine

Experimental: ARC-520 Cohort 8 - Single dose, intravenous administration of ARC-520 at 6.0 mg/kg 0.9 mL/min + diphenhydramine
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Timepoint [1] 0 0
post-dose through the end of study (Day 15 ± 1 day) plus 30 days
Secondary outcome [1] 0 0
Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24) of the Analytes of ARC-520
Timepoint [1] 0 0
Day 1 pre-dose through 48 hours post-dose
Secondary outcome [2] 0 0
Pharmacokinetics: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Plasma Concentration (AUClast) of the Analytes of ARC-520
Timepoint [2] 0 0
Day 1 pre-dose through 48 hours post-dose
Secondary outcome [3] 0 0
Pharmacokinetics: Area Under the Plasma Concentration Versus Time Curve From Zero Extrapolated to Infinity (AUCinf) of the Analytes of ARC-520
Timepoint [3] 0 0
Day 1 pre-dose through 48 hours post-dose
Secondary outcome [4] 0 0
Pharmacokinetics: Maximum Plasma Concentration (Cmax) of the Analytes of ARC-520
Timepoint [4] 0 0
Day 1 pre-dose through 48 hours post-dose
Secondary outcome [5] 0 0
Pharmacokinetics: Clearance (CL) of the Analytes of ARC-520
Timepoint [5] 0 0
Day 1 pre-dose through 48 hours post-dose
Secondary outcome [6] 0 0
Pharmacokinetics: Apparent Volume of Distribution (V) of the Analytes of ARC-520
Timepoint [6] 0 0
Day 1 pre-dose through 48 hours post-dose
Secondary outcome [7] 0 0
Pharmacokinetics: Terminal Elimination Rate Constant (Lambda z) of the Analytes of ARC-520
Timepoint [7] 0 0
Day 1 pre-dose through 48 hours post-dose
Secondary outcome [8] 0 0
Pharmacokinetics: Half-Life (t1/2) of the Analytes of ARC-520
Timepoint [8] 0 0
Day 1 pre-dose through 48 hours post-dose

Eligibility
Key inclusion criteria
* Male or female, 18-55 years of age, inclusive
* Able to provide written informed consent
* BMI between 19.0 and 35.0 kg/m2, inclusive
* 12-lead ECG at Screening and pre-dose with no clinically significant abnormalities
* Highly effective, double barrier contraception (both male and female partners) during the study and for 3 months following the dose of ARC-520
* Willing and able to comply with all study assessments
* Suitable venous access for blood sampling
* Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and creatinine levels in the normal range
* No abnormal finding of clinical relevance
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
* Pregnant/lactating
* Acute signs of hepatitis/other infection within 4 weeks of Screening
* Concurrent use of anticoagulants, corticosteroids, immunomodulators, or immunosuppressants.
* Use of prescription medication within 14 days prior to study treatment
* Depot injection/implant other than birth control within 3 months of study treatment
* Known diagnosis of diabetes mellitus
* History of autoimmune disease especially autoimmune hepatitis.
* Human immunodeficiency virus (HIV) infection
* Sero-positive for hepatitis B virus (HBV) or hepatitis C virus (HCV)
* Uncontrolled hypertension: blood pressure (BP) > 150/100 mmHg
* History of cardiac rhythm disturbances
* Family history of congenital long QT syndrome, Brugada syndrome or unexplained sudden cardiac death.
* Currently uses medications known to prolong the corrected QT interval (QTc).
* Symptomatic heart failure (per New York Heart Association guidelines)
* Unstable angina, myocardial infarction, severe cardiovascular disease, transient ischemic attack (TIA) or cerebrovascular accident (CVA) within past 6 months
* History of malignancy within last 5 years except for adequately treated basal cell carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical cancer
* Major surgery within 3 months of Screening
* History of alcohol and/or drug abuse < 12 months from Screening
* Regular use of alcohol within 6 months of Screening
* Evidence of systemic acute inflammation, sepsis or hemolysis.
* Clinically significant psychiatric disorder
* Use of recreational drugs within 3 months of Screening or drugs, such as cocaine, phencyclidine (PCP), and methamphetamines, within 1 year of Screening
* Positive urine drug screen
* History of allergy or hypersensitivity reaction to bee venom
* Positive reaction to the bee venom immunoglobulin E [IgE] test
* Use of investigational agents or devices within 30 days of study dosing or current participation in an investigational study.
* Clinically significant history/presence of any gastrointestinal pathology, unresolved gastrointestinal symptoms, liver or kidney disease
* Cholangitis, cholecystitis, cholestasis, or duct obstruction
* Clinically significant history/presence of neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, metabolic or other uncontrolled systemic disease
* Blood donation or blood loss (500 mL) within 30 days prior to study treatment
* History of fever within 2 weeks of Screening.
* Excessive exercise/physical activity within 7 days of Screening or enrollment or planned during the study.
* History of coagulopathy, stroke within six (6) months of baseline, and/or concurrent anticoagulant medication(s)

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/08/2016
Sample size
Target
Accrual to date
Final
40
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 0 0
QPharm, Pty Limited, Royal Brisbane Hospital - Herston
Recruitment postcode(s) [1] 0 0
4029 - Herston

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Arrowhead Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results are available at https://clinicaltrials.gov/study/NCT02535416